| Oct 24 |
LifeMD launches TestoRx, direct to consumer testosterone replacement therapy
|
| Oct 24 |
LifeMD® to Report Third Quarter 2024 Financial Results on November 7
|
| Oct 23 |
LifeMD® Launches TestoRx, a New Rex MD® Direct-to-Consumer Testosterone Replacement Therapy Telehealth Offering
|
| Oct 12 |
LifeMD, Inc.'s (NASDAQ:LFMD) top owners are retail investors with 45% stake, while 38% is held by institutions
|
| Sep 24 |
LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
|
| Sep 23 |
LifeMD: Are The Commons Too Cheap?
|
| Sep 19 |
LifeMD Announces Major Enhancements to its Weight Management Program, Expanding Patient Access to Branded GLP-1 Therapies and Introducing New Treatment Options
|
| Sep 10 |
LifeMD: Selling WorkSimpli Could Be A Catalyst
|
| Aug 26 |
LifeMD to Participate in Three Investor Conferences During September
|
| Aug 10 |
Analyst Estimates: Here's What Brokers Think Of LifeMD, Inc. (NASDAQ:LFMD) After Its Second-Quarter Report
|
